TrasGEX (alternative names: Glycooptimised TrastuzuMab-GEX; GT-Mab 7.3-GEX; TrasGEX; TrastuzuMab-GEX) is an anti-HER2 mAb that exhibits increased binding affinity for all FcγRIIIa variants expressed on immune effector cells. Compared to its parent antibody—trastuzumab, defucosylated TrasGEX showed significantly improved cell killing in ADCC-based assays and a higher activity in models in vivo. In addition, TrasGEX is currently being evaluated in clinical phase II trials and has shown good clinical activity in patients with HER2-positive solid tumors.
TrasGEX is a second-generation glycosylated antibody developed to meet the needs of a new therapy exhibiting higher activity on Her2-positive cancers. The glycosylation process used to develop this agent is achieved by reducing the fucosylation in the Fc region of the mAb molecule, resulting in increased binding affinity of the agent for the FcγRIII receptor on immune effector cells.
TrasGEX is derived from a parent antibody—trastuzumab. TrasGEX and trastuzumab bind to the same epitope of HER2 and thus, allow for competition and substitution between these two antibodies. Similar to the MOA of trastuzumab, glyco-engineered TrasGEX is thought to exhibit its therapeutic activity against HER2-positive tumors because of:
Fig.1 Mechanism of action of Trastuzumab.
|NCT ID||Status||Conditions||Lead Sponsor||Phase||Update Time|
|NCT01409343||Completed||Solid Tumors||Glycotope GmbH||Phase 1||December 20, 2013|
For more detailed information, please do not hesitate to contact us.
Creative Biolabs provides luciferase-based ADCC assay. This Jurkat cell based assay is pioneered by Creative Biolabs, and the methodology is very well accepted by the field. See attached ADCC Reporter Assay Protocol for further details.
All products and services are for Research Use Only. Do Not use in humans.
ADCC Assay WT vs AfucoTM Mabs Visit
Antibody Fc Engineering: Towards Better Therapeutics Visit
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.